FORM 5
[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ] Form 3 Holdings Reported
[ ] Form 4 Transactions Reported		 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

                                                                                  
 OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden
hours per response... 1.0
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

AXA IM Prime Impact Master Fund I SCA SICAV-RAIF		2. Issuer Name and Ticker or Trading Symbol

REVELATION BIOSCIENCES, INC. [REVB]		 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
_____ Officer (give title below)    __X__ Other (specify below)
Former 10% Owner
(Last)          (First)          (Middle)

2-4 RUE EUGENE RUPPERT,  		3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY)
12/31/2022 
(Street)

LUXEMBOURG, N4 L-2453
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed(MM/DD/YYYY)
 
6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form Filed by One Reporting Person
_X_ Form Filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		2. Trans. Date2A. Deemed Execution Date, if any3. Trans. Code
(Instr. 8)		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Amount(A) or (D)Price
Common stock 1/10/2022 (1) J (1)1958984 (1)A$0 (1)1958984 (1)D (2)(3)(4) 

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date
(MM/DD/YYYY)		7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year
(Instr. 4)		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of publicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement
(2) The following parties may be deemed to have the power to vote and direct the disposition of the shares of Common Stock owned by AXA IM Prime Impact Master Fund ISCA SICAV-RAIF (the "Fund"):(a) the Fund owns the shares of Common Stock reported herein, (b) the general partner of the Fund, AXA IM Prime Impact GP S.a.r.l, has appointed AXA Investment Managers Paris S.A. ("AIFM") as the alternative investment fund manager of the Fund to undertake all functions required of an external alternative investment fund manager, (c) the Fund with the consent of AIFM and duly represented by its general partner, AXA IM Prime Impact GP S.a.r.l, has also entered into a delegated portfolio management agreement with AIFM and AXA Investment Managers UK Ltd. ("AXA IM UK") in order to appoint AXA IM UK to act as the portfolio manager of the Fund, (d) AXA Investment Managers S.A. is the sole shareholder of AIFM and AXA IM UK, and (e) AXA S.A. is the controlling shareholder of AXA IM SA.
(3) The reporting persons do not believe that they constitute a "group" within the meaning of Rule 13d-5 under the Securities Exchange Act of 1934, as amended, and they do not believe that they are otherwise required to attribute to each other the beneficial ownership of the securities reported herein held by them or by any persons or entities for whom or for which AIFM or AXA IM UK provides investment management services. Each of the reporting persons also disclaims beneficial ownership of these securities except to the extent of that person's pecuniary interest therein.
(4) On July 28, 2022, the issuer closed a public offering, and, as a result of the dilutive effect of the public offering, the reporting persons ceased to beneficially own more than 10% of the issuer's Common Stock outstanding as of the close of business on July 28, 2022.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
AXA IM Prime Impact Master Fund I SCA SICAV-RAIF
2-4 RUE EUGENE RUPPERT
LUXEMBOURG, N4 L-2453


Former 10% Owner
AXA IM Prime Impact GP S.a.r.l
2-4, RUE EUGENE RUPPERT
LUXEMBOURG, N4 L-2453


Former 10% owner
AXA Investment Managers Paris
6 PLACE DE LA PYRAMIDE
PUTEAUX, I0 92800


Former 10% owner
AXA INVESTMENT MANAGERS UK Ltd
22 BISHOPGATE
LONDON, X0 EC2M 3XJ


Former 10% owner
AXA Investment Managers S.A.
6 PLACE DE LA PYRAMIDE
TOUR MAJUNGA
PUTEAUX, I0 92800


Former 10% owner
AXA S.A.
25 AVENUE MATIGNON
PARIS, I0 75008


Former 10% owner
Signatures
/s/ Mirko Dietz Board Member, AXA IM Prime Impact GP S.a.r.l2/14/2023
**Signature of Reporting PersonDate

/s/ Paul Guillaume Board Member, AXA IM Prime Impact GP S.a.r.l2/14/2023
**Signature of Reporting PersonDate

/s/ Mirko Dietz Board Member, AXA IM Prime Impact GP S.a.r.l2/14/2023
**Signature of Reporting PersonDate

/s/ Paul Guillaume Board Member, AXA IM Prime Impact GP S.a.r.l2/14/2023
**Signature of Reporting PersonDate

/s/ Enguerran Six Chief Compliance officer, AXA Investment Managers Paris S.A2/14/2023
**Signature of Reporting PersonDate

/s/ Terrance Turner Chief Compliance Officer, AXA Investment Managers UK Ltd2/14/2023
**Signature of Reporting PersonDate

/s/ Anthony Gilsoul Attorney-in-fact AXA Investment Managers S.A2/14/2023
**Signature of Reporting PersonDate

/s/ Anthony Gilsoul Attorney-in-fact AXA S.A2/14/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Petra Acquisition (NASDAQ:PAIC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Petra Acquisition.
Petra Acquisition (NASDAQ:PAIC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Petra Acquisition.